fa A Randomized, Double-blind, Placebo - controlled Study of Safety of the Adjunctive Saffron on Sexual Dysfunction Induced by a Selective Serotonin Reuptake Inhibitor فارماكولوژی و سم شناسی Pharmacology & Toxicology مروری Review <div dir="ltr" style="text-align: justify;"><strong>Background: </strong>Recent studies have indicated potential of saffron for applying in a wide variety of diseases such as psychiatric and neurologic disorders. The concurrent use of saffron with SSRIs can lead to reducing the dose of SSRIs. Saffron at a dose of 200 mg may change some hematological and biochemical parameters. <strong>Objective:</strong> The goal of this trial was to assess the safety of concomitant administration of saffron and SSRI in patients with major depressive disorder (MDD). <strong>Methods: </strong>Twenty adult outpatients between 18 to 55 years-old with the diagnosis of MDD who were receiving an SSRI for at least 1 month prior to the initiation of the study entered this double-blind trial. They were randomly assigned to receive capsule of saffron (15 mg twice daily) or placebo. Some laboratory parameters were measured at baseline and week 4 of the study. Other side effects checked on a prepared list of side effects, were systematically recorded throughout the study at baseline and on a weekly basis. <strong>Results:</strong> Saffron as an add-on medication to SSRIs for 4 weeks did not cause any statistically significant changes in laboratory parameters including AST, ALT, ALP, BUN, Cr., FBS, TG, TC, WBC, RBC, Hgb, Ht, PT, INR, and Pl count. <strong>Conclusion:</strong> This preliminary study provides safety evidences of concurrent intake of saffron and SSRI.</div> <div dir="ltr" style="text-align: justify;"><strong>Background: </strong>Recent studies have indicated potential of saffron for applying in a wide variety of diseases such as psychiatric and neurologic disorders. The concurrent use of saffron with SSRIs can lead to reducing the dose of SSRIs. Saffron at a dose of 200 mg may change some hematological and biochemical parameters. <strong>Objective:</strong> The goal of this trial was to assess the safety of concomitant administration of saffron and SSRI in patients with major depressive disorder (MDD). <strong>Methods: </strong>Twenty adult outpatients between 18 to 55 years-old with the diagnosis of MDD who were receiving an SSRI for at least 1 month prior to the initiation of the study entered this double-blind trial. They were randomly assigned to receive capsule of saffron (15 mg twice daily) or placebo. Some laboratory parameters were measured at baseline and week 4 of the study. Other side effects checked on a prepared list of side effects, were systematically recorded throughout the study at baseline and on a weekly basis. <strong>Results:</strong> Saffron as an add-on medication to SSRIs for 4 weeks did not cause any statistically significant changes in laboratory parameters including AST, ALT, ALP, BUN, Cr., FBS, TG, TC, WBC, RBC, Hgb, Ht, PT, INR, and Pl count. <strong>Conclusion:</strong> This preliminary study provides safety evidences of concurrent intake of saffron and SSRI.</div> Saffron, <,i>,Crocus sativus<,/i>,, Adverse effects, SSRI, MDD Saffron, <,i>,Crocus sativus<,/i>,, Adverse effects, SSRI, MDD 121 130 http://jmp.ir/browse.php?a_code=A-10-180-1&slc_lang=fa&sid=1 P Mansoori P Mansoori 100319475328460037649 100319475328460037649 No School of Pharmacy, Tehran University of Medical Sciences School of Pharmacy, Tehran University of Medical Sciences S Akhondzadeh S Akhondzadeh 100319475328460037650 100319475328460037650 No School of Pharmacy, Tehran University of Medical Sciences School of Pharmacy, Tehran University of Medical Sciences F Raisi F Raisi 100319475328460037651 100319475328460037651 No School of Pharmacy, Tehran University of Medical Sciences School of Pharmacy, Tehran University of Medical Sciences P Ghaeli P Ghaeli mmppg@yahoo.com 100319475328460037652 100319475328460037652 Yes School of Pharmacy, Tehran University of Medical Sciences School of Pharmacy, Tehran University of Medical Sciences AH Jamshidi AH Jamshidi 100319475328460037653 100319475328460037653 No Department of Pharmacognosy and Pharmaceutics, Institute of Medicinal Plants, ACECR Department of Pharmacognosy and Pharmaceutics, Institute of Medicinal Plants, ACECR AA Nasehi AA Nasehi 100319475328460037654 100319475328460037654 No School of Pharmacy, Tehran University of Medical Sciences School of Pharmacy, Tehran University of Medical Sciences H Sohrabi H Sohrabi 100319475328460037655 100319475328460037655 No School of Pharmacy, Tehran University of Medical Sciences School of Pharmacy, Tehran University of Medical Sciences S Saroukhani S Saroukhani 100319475328460037656 100319475328460037656 No School of Pharmacy, Tehran University of Medical Sciences School of Pharmacy, Tehran University of Medical Sciences